PepGen (PEPG) Competitors $1.25 +0.02 (+1.54%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PEPG vs. ACTU, NKTX, NVCT, CYBN, BIOA, GLSI, CRDF, DERM, CLLS, and MEIPShould you be buying PepGen stock or one of its competitors? The main competitors of PepGen include Actuate Therapeutics (ACTU), Nkarta (NKTX), Nuvectis Pharma (NVCT), Cybin (CYBN), BioAge Labs (BIOA), Greenwich LifeSciences (GLSI), Cardiff Oncology (CRDF), Journey Medical (DERM), Cellectis (CLLS), and MEI Pharma (MEIP). These companies are all part of the "pharmaceutical products" industry. PepGen vs. Its Competitors Actuate Therapeutics Nkarta Nuvectis Pharma Cybin BioAge Labs Greenwich LifeSciences Cardiff Oncology Journey Medical Cellectis MEI Pharma Actuate Therapeutics (NASDAQ:ACTU) and PepGen (NASDAQ:PEPG) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation. Do institutionals & insiders believe in ACTU or PEPG? 58.0% of PepGen shares are owned by institutional investors. 69.3% of Actuate Therapeutics shares are owned by company insiders. Comparatively, 5.2% of PepGen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media favor ACTU or PEPG? In the previous week, Actuate Therapeutics had 12 more articles in the media than PepGen. MarketBeat recorded 13 mentions for Actuate Therapeutics and 1 mentions for PepGen. Actuate Therapeutics' average media sentiment score of 0.07 beat PepGen's score of 0.00 indicating that Actuate Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actuate Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PepGen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better earnings & valuation, ACTU or PEPG? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioActuate TherapeuticsN/AN/A-$27.28MN/AN/APepGenN/AN/A-$89.98M-$2.96-0.42 Do analysts recommend ACTU or PEPG? Actuate Therapeutics currently has a consensus target price of $20.50, indicating a potential upside of 167.62%. PepGen has a consensus target price of $7.67, indicating a potential upside of 513.33%. Given PepGen's higher possible upside, analysts clearly believe PepGen is more favorable than Actuate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actuate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00PepGen 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Is ACTU or PEPG more profitable? PepGen's return on equity of -92.51% beat Actuate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Actuate TherapeuticsN/A -19,736.59% -281.83% PepGen N/A -92.51%-70.39% SummaryActuate Therapeutics beats PepGen on 5 of the 9 factors compared between the two stocks. Get PepGen News Delivered to You Automatically Sign up to receive the latest news and ratings for PEPG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PEPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PEPG vs. The Competition Export to ExcelMetricPepGenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$41M$3.11B$5.73B$9.56BDividend YieldN/A2.23%4.53%4.08%P/E Ratio-0.4220.4330.4625.16Price / SalesN/A238.53392.5787.62Price / CashN/A42.3737.0358.50Price / Book0.587.918.956.21Net Income-$89.98M-$54.72M$3.26B$265.38M7 Day Performance-3.10%1.66%1.06%-1.13%1 Month Performance-5.30%5.88%4.31%-0.71%1 Year Performance-87.31%8.72%28.39%18.86% PepGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PEPGPepGen3.0586 of 5 stars$1.25+1.6%$7.67+513.3%-87.4%$41MN/A-0.4230ACTUActuate TherapeuticsN/A$8.25+1.6%$20.50+148.5%-9.2%$166.22MN/A0.0010News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionNKTXNkarta2.0272 of 5 stars$2.35+0.9%$13.60+478.7%-55.8%$165.49MN/A-1.59140NVCTNuvectis Pharma3.781 of 5 stars$6.45+0.3%$15.33+137.7%-9.5%$163.69MN/A-5.518Positive NewsCYBNCybin2.4601 of 5 stars$6.92-2.0%$85.00+1,128.3%N/A$163.24MN/A-1.5850Trending NewsAnalyst RevisionBIOABioAge LabsN/A$4.52-0.7%N/AN/A$163.12M$3.86M0.00N/AGLSIGreenwich LifeSciences1.4422 of 5 stars$12.01-1.3%$39.00+224.7%-13.6%$162.69MN/A-8.833News CoverageEarnings ReportAnalyst ForecastCRDFCardiff Oncology1.6216 of 5 stars$2.43-0.4%$10.10+315.6%-0.9%$162.32M$680K-2.7920Positive NewsDERMJourney Medical1.7193 of 5 stars$7.00+0.7%$10.83+54.8%+58.9%$161.91M$56.13M-18.4290Analyst RevisionCLLSCellectis3.3286 of 5 stars$2.90+1.8%$4.00+37.9%+22.6%$158.41M$49.22M-3.54290Short Interest ↓MEIPMEI Pharma1.7475 of 5 stars$4.88-0.2%N/A+47.6%$158.28M$65.30M-1.03100 Related Companies and Tools Related Companies Actuate Therapeutics Alternatives Nkarta Alternatives Nuvectis Pharma Alternatives Cybin Alternatives BioAge Labs Alternatives Greenwich LifeSciences Alternatives Cardiff Oncology Alternatives Journey Medical Alternatives Cellectis Alternatives MEI Pharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PEPG) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PepGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PepGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access